Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx; M Valgimigli; P Juni; C Hamm; PG Steg; D Heg; GA Es; EP McFadden; Yoshinobu Onuma; C van Meijeren; P Chichareon; E Benit; H Mollmann; L Janssens; M Ferrario; A Moschovitis; A Zurakowski; M Dominici; Robert Jan van Geuns; K Huber; T Slagboom; PWJC (Patrick) Serruys; S Windecker

doi:10.1016/s0140-6736(18)31858-0

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx
, M Valgimigli
, P Juni
, C Hamm
, PG Steg
, D Heg
, GA Es
, EP McFadden
, Yoshinobu Onuma
, C van Meijeren
, P Chichareon
, E Benit
, H Mollmann
, L Janssens
, M Ferrario
, A Moschovitis
, A Zurakowski
, M Dominici
, Robert Jan van Geuns
, K Huber

T Slagboom, PWJC (Patrick) Serruys, S Windecker

Cardiology

Research output: Contribution to journal › Article › Academic › peer-review

710 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	940-949
Number of pages	10
Journal	Lancet (UK)
Volume	392
Issue number	10151
DOIs	https://doi.org/10.1016/s0140-6736(18)31858-0
Publication status	Published - 2018

Research programs

EMC COEUR-09

Access to Document

10.1016/s0140-6736(18)31858-0

http://hdl.handle.net/1765/114127

Cite this

Vranckx, P., Valgimigli, M., Juni, P., Hamm, C., Steg, PG., Heg, D., Es, GA., McFadden, EP., Onuma, Y., van Meijeren, C., Chichareon, P., Benit, E., Mollmann, H., Janssens, L., Ferrario, M., Moschovitis, A., Zurakowski, A., Dominici, M., van Geuns, R. J., ... Windecker, S. (2018). Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet (UK), 392(10151), 940-949. https://doi.org/10.1016/s0140-6736(18)31858-0

Vranckx, Pascal ; Valgimigli, M ; Juni, P et al. / Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. In: Lancet (UK). 2018 ; Vol. 392, No. 10151. pp. 940-949.

@article{20d17acd84c445d594036cf5f869d1ff,

title = "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial",

author = "Pascal Vranckx and M Valgimigli and P Juni and C Hamm and PG Steg and D Heg and GA Es and EP McFadden and Yoshinobu Onuma and \{van Meijeren\}, C and P Chichareon and E Benit and H Mollmann and L Janssens and M Ferrario and A Moschovitis and A Zurakowski and M Dominici and \{van Geuns\}, \{Robert Jan\} and K Huber and T Slagboom and Serruys, \{PWJC (Patrick)\} and S Windecker",

year = "2018",

doi = "10.1016/s0140-6736(18)31858-0",

language = "Undefined/Unknown",

volume = "392",

pages = "940--949",

journal = "Lancet (UK)",

issn = "0140-6736",

publisher = "Elsevier",

number = "10151",

}

Vranckx, P, Valgimigli, M, Juni, P, Hamm, C, Steg, PG, Heg, D, Es, GA, McFadden, EP, Onuma, Y, van Meijeren, C, Chichareon, P, Benit, E, Mollmann, H, Janssens, L, Ferrario, M, Moschovitis, A, Zurakowski, A, Dominici, M, van Geuns, RJ, Huber, K, Slagboom, T, Serruys, PWJC & Windecker, S 2018, 'Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial', Lancet (UK), vol. 392, no. 10151, pp. 940-949. https://doi.org/10.1016/s0140-6736(18)31858-0

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. / Vranckx, Pascal; Valgimigli, M; Juni, P et al.
In: Lancet (UK), Vol. 392, No. 10151, 2018, p. 940-949.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

AU - Vranckx, Pascal

AU - Valgimigli, M

AU - Juni, P

AU - Hamm, C

AU - Steg, PG

AU - Heg, D

AU - Es, GA

AU - McFadden, EP

AU - Onuma, Yoshinobu

AU - van Meijeren, C

AU - Chichareon, P

AU - Benit, E

AU - Mollmann, H

AU - Janssens, L

AU - Ferrario, M

AU - Moschovitis, A

AU - Zurakowski, A

AU - Dominici, M

AU - van Geuns, Robert Jan

AU - Huber, K

AU - Slagboom, T

AU - Serruys, PWJC (Patrick)

AU - Windecker, S

PY - 2018

Y1 - 2018

U2 - 10.1016/s0140-6736(18)31858-0

DO - 10.1016/s0140-6736(18)31858-0

M3 - Article

SN - 0140-6736

VL - 392

SP - 940

EP - 949

JO - Lancet (UK)

JF - Lancet (UK)

IS - 10151

ER -

Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet (UK). 2018;392(10151):940-949. doi: 10.1016/s0140-6736(18)31858-0